|
74
|
228
|
4o7yA |
Saicar synthetase (type-2) in complex with cmp |
|
107
|
299
|
4orkA |
Crystal structure of the phosphotransferase domain of the bifunctional aminoglycoside resistance enzyme aac(6')-ie-aph(2'')-ia |
|
109
|
346
|
4nctC |
Human dyrk1a in complex with pkc412 |
|
77
|
232
|
4o7wA |
Saicar synthetase (type-2) in complex with atp and tdp |
|
85
|
343
|
4ntsA |
Apo structure of the catalytic subunit of camp-dependent protein kinase |
|
97
|
336
|
4otdA |
Crystal structure of prk1 catalytic domain |
|
96
|
330
|
4nh1A |
Crystal structure of a heterotetrameric ck2 holoenzyme complex carrying the andante-mutation in ck2beta and consistent with proposed models of autoinhibition and trans-autophosphorylation |
|
79
|
275
|
4n70A |
Pim1 complexed with a pyridylcarboxamide |
|
75
|
227
|
4o86A |
Saicar synthetase (type-2) in complex with adp and cdp |
|
95
|
306
|
4o91A |
Crystal structure of type ii inhibitor ng25 bound to tak1-tab1 |
|
86
|
302
|
4nt4A |
Crystal structure of the kinase domain of gilgamesh isoform i from drosophila melanogaster |
|
74
|
228
|
4o7vA |
Saicar synthetase (type-2) in complex with adp and udp/ump |
|
75
|
225
|
4o7tA |
Saicar synthetase (type-2) in complex with adp, asp and tmp |
|
87
|
293
|
4o0rA |
Back pocket flexibility provides group-ii pak selectivity for type 1 kinase inhibitors |
|
47
|
163
|
4o96A |
2.60 angstrom resolution crystal structure of a protein kinase domain of type iii effector nleh2 (ecs1814) from escherichia coli o157:h7 str. sakai |
|
87
|
302
|
4nk9A |
Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 1 |
|
81
|
298
|
4nj3A |
Modulating the interaction between cdk2 and cyclin a with a quinoline-based inhibitor |
|
84
|
273
|
4n6zA |
Pim1 complexed with a pyridylcarboxamide |
|
84
|
292
|
4o0tA |
Back pocket flexibility provides group-ii pak selectivity for type 1 kinase inhibitors |
|
154
|
465
|
4mx9A |
Cdpk1 from neospora caninum in complex with inhibitor uw1294 |
|
74
|
228
|
4o7rA |
Saicar synthetase (type-2) in complex with ump/udp |
|
86
|
298
|
4nksA |
Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 3 |
|
90
|
263
|
4otqA |
Crystal structure of btk kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-2-methyl-phenyl]-1-methyl-2-oxo-3-pyridyl]-3-methyl-urea |
|
113
|
352
|
4nifB |
Heterodimeric structure of erk2 and rsk1 |
|
111
|
329
|
4oucA |
Structure of human haspin in complex with histone h3 substrate |
|
88
|
335
|
4otiA |
Crystal structure of prk1 catalytic domain in complex with tofacitinib |
|
112
|
347
|
4nctA |
Human dyrk1a in complex with pkc412 |
|
82
|
277
|
4mxoA |
Human src kinase bound to kinase inhibitor bosutinib |
|
147
|
455
|
4mvfA |
Crystal structure of plasmodium falciparum cdpk2 complexed with inhibitor staurosporine |
|
79
|
277
|
4mxzA |
Src m314l t338m double mutant bound to kinase inhibitor bosutinib |
|
79
|
277
|
4mxyA |
Src m314l t338m double mutant bound to kinase inhibitor bosutinib |
|
155
|
465
|
4mxaA |
Cdpk1 from neospora caninum in complex with inhibitor rm-1-132 |
|
98
|
295
|
4mxcA |
Crystal structure of cmet in complex with novel inhibitor |
|
76
|
274
|
4mblA |
Discovery of pyrazolo[1,5a]pyrimidine-based pim1 inhibitors |
|
62
|
284
|
4m3qA |
Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in complex with inhibitor unc1917 |
|
75
|
277
|
4mxxA |
Human src a403t mutant bound to kinase inhibitor bosutinib |
|
92
|
263
|
4m0yA |
Crystal structure of itk in complex with compound 1 [4-(carbamoylamino)-1-(naphthalen-1-yl)-1h-pyrazole-3-carboxamide] |
|
122
|
346
|
4mq1A |
The crystal structure of dyrk1a with a bound pyrido[2,3-d]pyrimidine inhibitor |
|
106
|
447
|
4ludA |
Crystal structure of hck in complex with the fluorescent compound skf86002 |
|
77
|
274
|
4mneB |
Crystal structure of the braf:mek1 complex |
|
111
|
349
|
4looA |
Structural basis of autoactivation of p38 alpha induced by tab1 (monoclinic crystal form) |
|
110
|
332
|
4md7E |
Crystal structure of full-length symmetric ck2 holoenzyme |
|
80
|
269
|
4lmuA |
Crystal structure of pim1 in complex with the inhibitor quercetin (resulting from displacement of skf86002) |
|
62
|
276
|
4mbjA |
Human b-raf kinase domain in complex with an imidazopyridine-based inhibitor |
|
81
|
303
|
4m8tA |
Rsk2 t493m c-terminal kinase domain in complex with 3-(3-(1h-pyrazol-4-yl)phenyl)-2-cyanoacrylamide |
|
79
|
277
|
4m69B |
Crystal structure of the mouse rip3-mlkl complex |
|
84
|
264
|
4m13A |
Crystal structure of itk in complex with compound 8 [4-(carbamoylamino)-1-(7-propoxynaphthalen-1-yl)-1h-pyrazole-3-carboxamide] |
|
75
|
251
|
4muqA |
Crystal structure of vancomycin resistance d,d-dipeptidase vanxyg in complex with d-ala-d-ala phosphinate analog |
|
110
|
363
|
4lv8A |
Murine irga6 bound to toxoplasma rop5c, a pseudokinase gdi |
|
196
|
640
|
4mk0A |
Crystal structure of g protein-coupled receptor kinase 2 in complex with a a rationally designed paroxetine derivative |
